A pooled analysis of two randomized trials has demonstrated the beneficial effects of empagliflozin in patients with heart failure with a reduced and preserved ejection fraction. The late breaking study is presented in a ...
Aug 27, 2021
0
2
Empagliflozin (trade name Jardiance) has been approved since May 2014 for adults with type 2 diabetes mellitus in whom diet and exercise alone do not provide adequate glycaemic control. The German Institute for Quality and ...
Nov 19, 2014
0
0
While the composite of death and heart failure hospitalizations was not significantly reduced, empagliflozin may help reduce heart failure risks after a heart attack
Apr 8, 2024
0
0
(HealthDay)—Empagliflozin does not increase the risk of bone fracture in patients with type 2 diabetes, according to a study published online June 15 in Diabetes Care.
Jul 23, 2018
0
0
Empagliflozin (trade name: Jardiance) has been approved since May 2014 for adults with type 2 diabetes mellitus in whom diet and exercise alone do not provide adequate glycaemic control. In 2014, the German Institute for ...
Jun 3, 2016
0
1
Adults treated with empagliflozin during hospitalization for acute heart failure experienced a clinical benefit such as increased survival, lower risk of heart failure hospital readmission and an overall improvement in their ...
Nov 15, 2021
0
3
More work needs to be done to examine the real world effects of the commonly prescribed diabetes drug empagliflozin, new research in the journal Diabetes Therapy finds.
Jun 14, 2017
0
0
